Santen Gets FDA Approval for Alamast Anti-Allergy Eye Drops

November 1999
Worldwide Biotech;Nov99, Vol. 11 Issue 11, p6
Trade Publication
Provides information on the United States Food and Drug Administration's approval for an ocular allergy medication ALAMAST developed by Santen Pharmaceutical Co.


Related Articles

  • Stop a Deadly peanut allergy. Dawidowska, Kasia; Harrar, Sari // Prevention;Aug2003, Vol. 55 Issue 8, p166 

    Discusses research being done on peanut allergy. Reference to a study published in the March 2003 issue of the 'New England Journal of Medicine'; Experimental drug that could reduce life-threatening reactions to peanut; Drug which is expected to receive U.S. Food and Drug Administration...

  • FDA Lifts '07 Hold on Allergy Therapeutics' Vaccines.  // BioWorld International;4/27/2011, Vol. 16 Issue 17, p3 

    The article reports that Allergy Therapeutics PLC shares climbed by 10% after the company stated that the U.S. Food and Drug Administration (FDA) has agreed to lift the 2007 hold on its allergy vaccines. The company hopes to move ahead to pinpoint a development and commercialization partner. The...

  • Latex allergy has become common; hand dermatitis may lead...  // Modern Medicine;Dec95, Vol. 63 Issue 12, p17 

    Reports on an acute latex-protein allergy. Those at risk; comments by B. Lauren Charous, MD of the American College Of Asthma, Allergy,and Immunology; Careful history of patient required; Presence of allergic antibodies in allergy to latex proteins; Hypersensitivity reactions; Complication of...

  • Desloratadine: A once-daily nonsedating antihistamine for seasonal allergic rhinitis and chronic idiopathic urticaria. Goldman, Monica // Formulary;May2001, Vol. 36 Issue 5, p329 

    Examines the effectiveness of desloratadine in treating allergic disorders in the United States. Chemistry and pharmacology; Pharmacokinetics; Approval for therapeutic use by the United States Food and Drug Administration.

  • A teachable moment for allergy tabs. Iskowitz, Marc // Medical Marketing & Media;Jun2014, Vol. 49 Issue 6, p14 

    The article reports that the sublingual allergy immunotherapy tablets (SLITS), the grass-pollen allergy tablet Oralair from Greer Laboratories Inc. and the Grastek for grass allergy and Ragwitek for ragweed pollen from Merck & Co. Inc., were approved by the U.S. Food and Drug Administration.

  • Unwanted Attention. Smith, Davis N. // Pharmaceutical Executive;Jun2001, Vol. 21 Issue 6, p44 

    Reports on the recommendation that allergy medications Claritin, Allegra and Zyrtec be changed from prescription to over-the-counter products by an advisory from the United States Food and Drug Administration. What makes the vote unique; Opposition of the drugs' manufacturers to a change in the...

  • Recent changes to FDA-approved labeling.  // American Journal of Health-System Pharmacy;8/1/2004, Vol. 61 Issue 15, p1537 

    Discusses the recent changes in the approved drug labeling of the U.S. Food and Drug Administration. Use of cetrorelix acetate in women with a severe allergic condition; Benefits from the doxapram hydrochloride in patients with a mechanical obstruction to ventilation; Indications for use of...

  • FDA warns of asenapine hypersensitivity.  // Reactions Weekly;9/10/2011, Issue 1368, p2 

    The article reports on the public advisory issued by the U.S. Food and Drug Administration on August 30, 2011 concerning a number of cases of adverse allergic reactions after taking the antipsychotic drug Saphris (asenapine).

  • FDA in favour of boxed warning for Xolair.  // Reactions Weekly;3/3/2007, Issue 1141, p4 

    The article reports that the U.S. Food and Drugs Administration (FDA) has requested Genentech to include a boxed warning to the labelling for omalizumab to warn about possible anaphylaxis which may include pruritus, urticaria, syncope, dizziness, chest tightness, trouble breathing and swelling...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics